A股異動 | 廣譽遠(600771.SH)漲6% 實控人或變為山西省國資委
格隆匯6月9日丨廣譽遠(600771.SH)股價V型反轉,集合競價高開逾8%,開盤迴吐全部漲幅後再度拉昇,現報24.19元,漲幅6.38%,最新總市值119億,換手率7%。公司昨日公吿稱,控股股東東盛集團同意將其質押給晉創投資的上市公司3150.9萬股股份(佔公司總股本的6.40%)過户抵償給晉創投資,用於清償其欠付晉創投資的相應債務。實施完成後,晉創投資將持有上市公司14.53%股份,東盛集團持股比例則降至5.86%。公司控股股東將由東盛集團變更為晉創投資,實控人由郭家學變更為山西省國資委。

Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.